Browsing: divi's labs

Shares of pharmaceutical companies came under selling pressure on Tuesday with Nifty Pharma index hitting…

Moderation from highs is imminent but long-term outlook intact; FY22e EPS up 13.5%; TP cut to Rs 5,300 Divi’s reported…

Divi’s Q2FY22 revenue/EBITDA missed our estimates by 2%/3% but PAT was a beat on lower taxes. Pfizer’s COVID-19 oral drug…